{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:09:39Z","timestamp":1783616979875,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s40265-013-0124-1","type":"journal-article","created":{"date-parts":[[2013,9,23]],"date-time":"2013-09-23T04:08:40Z","timestamp":1379909320000},"page":"1617-1625","source":"Crossref","is-referenced-by-count":35,"title":["Ocriplasmin: A Review of Its Use in Patients with Symptomatic Vitreomacular Adhesion"],"prefix":"10.1007","volume":"73","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohita","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,24]]},"reference":[{"key":"124_CR1","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2147\/OPTH.S14840","volume":"5","author":"EW Schneider","year":"2011","unstructured":"Schneider EW, Johnson MW. Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review. Clin Ophthalmol. 2011;5:1151\u201365.","journal-title":"Clin Ophthalmol."},{"issue":"4","key":"124_CR2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1586\/eop.12.34","volume":"7","author":"A Girach","year":"2012","unstructured":"Girach A, Pakola S. Vitreomacular interface diseases: pathophysiology, diagnosis and future treatment options. Expert Rev Ophthalmol. 2012;7(4):311\u201323.","journal-title":"Expert Rev Ophthalmol."},{"key":"124_CR3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/B978-0-12-374203-2.00256-6","volume-title":"Encyclopedia of the eye","author":"J Sebag","year":"2010","unstructured":"Sebag J. Vitreous anatomy, aging, and anomalous posterior vitreous detachment. In: Dartt DA, Beharse JC, Dana R, editors. Encyclopedia of the eye. Oxford: Academic Press; 2010. p. 307\u201315."},{"issue":"8","key":"124_CR4","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s00417-004-0980-1","volume":"242","author":"J Sebag","year":"2004","unstructured":"Sebag J. Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch Clin Exp Ophthalmol. 2004;242(8):690\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"issue":"6","key":"124_CR5","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.survophthal.2012.01.011","volume":"57","author":"ARH Simpson","year":"2012","unstructured":"Simpson ARH, Petrarca R, Jackson TL. Vitreomacular adhesion and neovascular age-related macular degeneration. Surv Ophthalmol. 2012;57(6):498\u2013509.","journal-title":"Surv Ophthalmol."},{"issue":"7","key":"124_CR6","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.ophtha.2009.01.052","volume":"116","author":"CA McCannel","year":"2009","unstructured":"McCannel CA, Ensminger JL, Diehl NN, et al. Population-based incidence of macular holes. Ophthalmology. 2009;116(7):1366\u20139.","journal-title":"Ophthalmology."},{"issue":"1","key":"124_CR7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0002-9394(14)73813-9","volume":"119","author":"T Hikichi","year":"1995","unstructured":"Hikichi T, Yoshida A, Trempe CL. Course of vitreomacular traction syndrome. Am J Ophthalmol. 1995;119(1):55\u201361.","journal-title":"Am J Ophthalmol."},{"key":"124_CR8","unstructured":"American Academy of Ophthalmology Retina\/Vitreous Panel. Preferred Practice Pattern guidelines: idiopathic macular hole. 2008. http:\/\/one.aao.org\/CE\/PracticeGuidelines\/PPP_Content.aspx?cid=6f2be59d-6481-4c64-9a3e-8d1dabec9ffa . Accessed 13 Aug 2013."},{"key":"124_CR9","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. Medical review(s). 2012. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/125422Orig1s000MedR.pdf . Accessed 13 Aug 2013."},{"key":"124_CR10","unstructured":"National Institute for Health and Care Excellence. Ocriplasmin for first line treatment of symptomatic vitreomacular adhesion. 2012. http:\/\/www.nice.org.uk\/media\/71F\/EB\/VitreomacularAdhesionAppendixBDraftScope.pdf . Accessed 13 Aug 2013."},{"key":"124_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000223938","volume":"44","author":"A Gandorfer","year":"2009","unstructured":"Gandorfer A. Objective of pharmacologic vitreolysis. Dev Ophthalmol. 2009;44:1\u20136.","journal-title":"Dev Ophthalmol."},{"key":"124_CR12","unstructured":"ThromboGenics. JETREA\u00ae (ocriplasmin): US prescribing information. 2012. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125422s000lbl.pdf http:\/\/jetrea.com\/JETREAPrescribingInformation.pdf . Accessed 13 Aug 2013."},{"key":"124_CR13","unstructured":"European Medicines Agency. JETREA (ocriplasmin): EU summary of product characteristics. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002381\/WC500142158.pdf . Accessed 13 Aug 2013."},{"issue":"3","key":"124_CR14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/02713680903484259","volume":"35","author":"AM Gad Elkareem","year":"2010","unstructured":"Gad Elkareem AM, Willikens B, Stassen JM, et al. Differential vitreous dye diffusion following microplasmin or plasmin pre-treatment. Curr Eye Res. 2010;35(3):235\u201341.","journal-title":"Curr Eye Res."},{"key":"124_CR15","first-page":"473","volume":"103","author":"J Sebag","year":"2005","unstructured":"Sebag J. Molecular biology of pharmacologic vitreolysis. Trans Am Ophthalmol Soc. 2005;103:473\u201394.","journal-title":"Trans Am Ophthalmol Soc."},{"issue":"12","key":"124_CR16","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3109\/02713680903308487","volume":"34","author":"W Chen","year":"2009","unstructured":"Chen W, Mo W, Sun K, et al. Microplasmin degrades fibronectin and laminin at vitreoretinal interface and outer retina during enzymatic vitrectomy. Curr Eye Res. 2009;34(12):1057\u201364.","journal-title":"Curr Eye Res."},{"issue":"2","key":"124_CR17","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1167\/iovs.08-2185","volume":"50","author":"MD Smet de","year":"2009","unstructured":"de Smet MD, Valmaggia C, Zarranz-Ventura J, et al. Microplasmin: ex vivo characterization of its activity in porcine vitreous. Invest Ophthalmol Vis Sci. 2009;50(2):814\u20139.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"4","key":"124_CR18","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s00417-006-0394-3","volume":"245","author":"J Sebag","year":"2007","unstructured":"Sebag J, Ansari RR, Suh KI. Pharmacologic vitreolysis with microplasmin increases vitreous diffusion coefficients. Graefes Arch Clin Exp Ophthalmol. 2007;245(4):576\u201380.","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"issue":"9","key":"124_CR19","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1167\/iovs.04-1517","volume":"46","author":"T Sakuma","year":"2005","unstructured":"Sakuma T, Tanaka M, Mizota A, et al. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. Invest Ophthalmol Vis Sci. 2005;46(9):3295\u20139.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"2","key":"124_CR20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1167\/iovs.03-0930","volume":"45","author":"A Gandorfer","year":"2004","unstructured":"Gandorfer A, Rohleder M, Sethi C, et al. Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci. 2004;45(2):641\u20137.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"7","key":"124_CR21","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/IAE.0b013e3181e0970a","volume":"30","author":"P Stalmans","year":"2010","unstructured":"Stalmans P, Delaey C, de Smet MD, et al. Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial). Retina. 2010;30(7):1122\u20137.","journal-title":"Retina."},{"issue":"4","key":"124_CR22","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ophtha.2009.11.005","volume":"117","author":"MS Benz","year":"2010","unstructured":"Benz MS, Packo KH, Gonzalez V, et al. A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy. Ophthalmology. 2010;117(4):791\u20137.","journal-title":"Ophthalmology."},{"key":"124_CR23","unstructured":"de Smet MD, Gandorfer A, Stalmans P, et al. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology. 2009; 116(7):1349\u201355, 55.e1\u20132."},{"key":"124_CR24","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. Pharmacology review(s). 2012. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/125422Orig1s000PharmR.pdf . Accessed 13 Aug 2013."},{"key":"124_CR25","unstructured":"European Medicines Agency. JETREA: EU assessment report. 2013. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002381\/WC500142228.pdf . Accessed 13 Aug 2013."},{"issue":"13","key":"124_CR26","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1167\/iovs.12-10148","volume":"53","author":"MD Smet de","year":"2012","unstructured":"de Smet MD, Jonckx B, Vanhove M, et al. Pharmacokinetics of ocriplasmin in vitreous. Invest Ophthalmol Vis Sci. 2012;53(13):8208\u201313.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"124_CR27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bpc.2012.03.002","volume":"165\u2013166","author":"F Aerts","year":"2012","unstructured":"Aerts F, Noppen B, Fonteyn L, et al. Mechanism of inactivation of ocriplasmin in porcine vitreous. Biophys Chem. 2012;165\u2013166:30\u20138.","journal-title":"Biophys Chem."},{"issue":"7","key":"124_CR28","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1056\/NEJMoa1110823","volume":"367","author":"P Stalmans","year":"2012","unstructured":"Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012;367(7):606\u201315.","journal-title":"N Engl J Med."},{"key":"124_CR29","unstructured":"Kuppermann BD. The phase III MIVI-TRUST clinical trial data: subgroup responder analysis of a single intravitreal injection of ocriplasmin in patients with vitreomacular traction [abstract no. 2754]. Annual Meeting of the Association for Research in Vision and Ophthalmology; 6\u201310 May 2012; Fort Lauderdale, FL."},{"key":"124_CR30","unstructured":"Pieramici DJ, Boyer DS. The phase III MIVI-TRUST clinical trial data: subgroup responder analysis of a single intravitreal of ocriplasmin in patients with full-thickness macular hole [abstract no. 947\/D991]. Annual Meeting of the Association for Research in Vision and Ophthalmology; 6\u201310 May 2012; Fort Lauderdale, FL."},{"key":"124_CR31","unstructured":"National Institute for Health and Care Excellence. Vitreomacular traction - ocriplasmin: appraisal consultation document. 2013. http:\/\/guidance.nice.org.uk\/TA\/WaveR\/144\/Consultation\/DraftGuidance . Accessed 13 Aug 2013."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0124-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0124-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0124-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:33Z","timestamp":1559490093000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0124-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":31,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["124"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0124-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}